Tag: Alzheimer’s
Two Major Health Systems Will Not Administer Controversial Aduhelm
Individual doctors can prescribe Aduhelm, but patients would have to go elsewhere to receive the drug via infusion
Late-Life Cognitive Activity May Delay Dementia
Taking up reading, puzzles, and games even in one's 80s may provide cognitive protection
Medicare Mulls Coverage for Controversial Drug for Alzheimer Disease
CMS says a final decision on coverage is not likely until next spring
Longer Reproductive Window Could Up Risk for Alzheimer Disease
Authors suggest longer exposure to endogenous estrogen may be associated with increased levels of Alzheimer disease biomarkers
FDA Head Asks for Investigation Into Alzheimer Disease Drug Approval
Request follows reports that Biogen and the FDA held off-the-books meetings before the drug's approval that may have violated FDA protocol
New Rx Instructions Tighten Use of Controversial Alzheimer Disease Drug
Major changes to prescribing instructions are rare, especially so soon after approval; change could curb the drug's use
Changes in Movement May Indicate Preclinical Alzheimer Disease
Changes in daytime fractal motor activity regulation may occur in women before cognitive symptoms of Alzheimer disease
House Committees to Investigate New Alzheimer Disease Drug Approval
FDA approved Aduhelm earlier this month, despite advisory committee's conclusion that there was not enough evidence to support its effectiveness
Lilly to Seek FDA Approval for New Drug for Alzheimer Disease
Donanemab has already received a 'breakthrough therapy' designation from the FDA
Three FDA Advisers Quit Over Agency Approval of Aduhelm
Several experts have said the available evidence about Aduhelm raises significant doubts about its effectiveness
